


ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

June 24, 2020



For more information: www.cdc.gov/COVID19

COVID-19 vaccination in the United States

Need for equitable access to safe and effective vaccines and evidence-based vaccination policy

- Preparing for implementation of **safe and effective** COVID-19 vaccines is a critical next step to protect the public and reduce the impact of COVID-19 on society
- Increased risk of severe COVID-19 in vulnerable populations and racial/ethnic minority groups highlight the need for:
 - **Diverse representation** in clinical trials
 - **Equitable access** to vaccines, regardless of vaccination strategy or priority groups
- ACIP COVID-19 vaccines work group established to help inform **evidence-based approaches** to COVID-19 vaccination policy

ACIP COVID-19 Vaccines Work Group

- **Established:** April 2020
- **Role:** Collection, analysis, and preparation of information related to COVID-19 vaccines for presentation, discussion, deliberation, and vote by the ACIP, using an open and transparent process.
- **Membership:** 41 members, including ACIP voting members, liaisons, *ex-officios*, and expert consultants



Expertise areas of COVID-19 Work Group members

- Epidemiology
- Vaccine safety
- Vaccinology
- Infectious diseases
- Immunology
- General medicine
- Geriatrics
- Pediatrics
- Obstetrics
- Immunocompromised hosts
- Vaccine administration/delivery
- Public health/surveillance
- Ethics
- Health equity
- Communications
- Emergency preparedness

COVID-19 Work Group composition


4 ACIP voting members

Chair

Beth Bell

Consultants



- Vaccinology
- Microbiology/Immunology
- Safety
- Ethics
- Health equity

Liaison representatives



Ex-officio/government members



CDC participants



Co-leads: Kathleen Dooling
Sarah Mbaeyi



CDC experts

ACIP COVID-19 Work Group Terms of Reference

- Policy topic under consideration: Use of COVID-19 vaccines in the U.S. population.
- Work Group activities:
 - Review safety and immunogenicity data for COVID-19 vaccines
 - Review the epidemiology of COVID-19 disease and identify potential target populations for vaccination
 - Discuss potential vaccine prioritization plans in the event of insufficient early COVID-19 vaccine supply
 - Identify areas where additional data are needed to inform COVID-19 vaccine recommendations
 - Develop COVID-19 vaccine policy options that ACIP may consider for recommendation
- Vaccine safety technical subgroup: advises the main Work Group on the safety of COVID-19 vaccines, both during clinical development and post-licensure

Decision-making in the context of many unknowns and uncertainties

- Stand for the principles of evidence-based decision-making, equity, and transparency in the process
- Tension between the need to provide guidance and the limited available science base
- Strive to develop a robust understanding of what is known; make sure diverse voices are heard
- Make decisions based on the knowns at the time
- Recognize from the start that revisions will be needed as more information becomes available
- Advocate for implementation of the essential strategies and systems to ensure that pivotal data for decision-making get collected
- Promote a feedback loop to evaluate the impact of recommendations and commit to revising accordingly

Today's agenda

- **COVID-19 vaccine development**
 - Dr. Matthew Hepburn (Lead, Operation Warp Speed Vaccines)
- **Landscape of COVID-19 vaccines in development**
 - Dr. Kathy Neuzil (University of Maryland)
- **COVID-19 vaccine prioritization considerations**
 - Dr. Sarah Mbaeyi (CDC)
- **Work Group considerations and next steps**
 - Dr. Kathleen Dooling (CDC)

Work group members

ACIP members

- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

Ex-officio/government members

- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Eric Deussing
- CMS: Jeff Kelman
- BARDA: Christine Oshansky

CDC Co-leads

- Kathleen Dooling
- Sarah Mbaeyi

Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

Liaisons, cont’d


- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Althea House (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: David Weber

Consultants

- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)

CDC participants

- Doug Campos-Outcalt
- Thomas Clark
- Amanda Cohn
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Sam Graitcer
- Lisa Grohskopf
- Rita Helfand
- Terri Hyde
- Tara Jatlaoui
- Cynthia Jorgensen
- Jessica MacNeil
- Rebecca Morgan
- Sara Oliver
- Anita Patel
- Stephanie Schrag
- Tom Shimabukuro
- Nathalie Thornburg
- Jennifer Verani
- Cindy Weinbaum
- Yon Yu
- Jane Zucker



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

